NEW DELHI (Reuters) – The Serum Institute of India, the world’s biggest vaccine makers, has sought the drug regulator’s permission to conduct a small domestic trial of the Novavax Inc COVID-19 vaccine that was found to be 89.3% effective in a UK trial, its CEO told Reuters on Friday.
(Reporting by Krishna N. Das; Editing by Shri Navaratnam)
